通腑化瘀方治疗非酒精性脂肪性肝病120例  

“Tongfu Huayu Decoction” for the treatment of nonalcoholic fatty liver disease:report of 120 cases

作　　者：芦亚君[1] 张爱军[1] 陈晓蓉[2] 

机构地区：[1]浙江省慈溪市人民医院感染科,浙江慈溪315300 [2]复旦大学附属上海市公共卫生临床中心,上海201508

出　　处：《上海中医药杂志》2014年第3期41-44,共4页Shanghai Journal of Traditional Chinese Medicine

基　　金：浙江省中医药科学研究基金A级项目(2011ZA099)

摘　　要：目的观察通腑化瘀方治疗非酒精性脂肪性肝病的临床疗效。方法将180例非酒精性脂肪性肝病患者随机分为治疗组120例和对照组60例,治疗组予通腑化瘀方口服,对照组予多烯磷脂酰胆碱胶囊口服。两组疗程均为3个月,观察临床疗效及体质量、体质量指数、腰臀比、肝功能、血脂、血糖、血尿酸、铁蛋白及CT影像脂肪肝分度的变化情况,并于疗程结束后3个月随访相关指标。结果①治疗组、对照组总有效率分别为92.50%、66.67%;组间临床疗效比较,差异有统计学意义(P<0.05)。②治疗后、停药3个月与治疗前组内比较,两组体质量、体质量指数、腰臀比、肝功能、铁蛋白、血糖、血脂、血尿酸水平差异均有统计学意义(P<0.05);治疗后与停药3个月后组内比较,两组各指标差异均无统计学意义(P>0.05)。组间治疗后比较,体质量、体质量指数、腰臀比、肝功能、铁蛋白、血糖、血脂、血尿酸水平差异均有统计学意义(P<0.05);组间停药3个月后比较,各指标差异均有统计学意义(P<0.05)。③治疗前后组内比较,两组CT影像脂肪肝分度差异均有统计学意义(P<0.05);组间治疗后比较,CT影像脂肪肝分度差异有统计学意义(P<0.05)。结论通腑化瘀方治疗非酒精性脂肪性肝病临床疗效显著,且远期疗效较佳。Objective To observe the clinical efficacy of ＂Tongfu Huayu Decoction＂ in treating nonalcoholic fatty liver disease （NAFLD）. Methods One hundred and eighty cases with NAFLD were randomized into two groups： treatment group in which 120 cases were treated by ＂Tongfu Huayu Decoction＂ orally, and control group in which 60 cases were treated by Polyene Phosphatidylcholine Capsule orally, with the course of 3 months. The clinical efficacy, body weight, body mass index, waist-hip ratio, liver function, lipid, glucose, blood uric acid, ferritin and fatty liver CT results were evaluateit before and after treatment. We follow-up visit the correlative indexes after 12 weeks treatment. Results ① The total effective rate was 92.50% in the treatment group and 66.67% in the control group, with a difference between the two groups（ P 〈 0.05 ）. ② In each group, there were significant differences in body weight, body mass index, waist hip ratio, liver function, and levels of ferritin, glucose, lipid and blood uric acid between before and after treatment or before treatment and 12 week after drug withdrawal （ P 〈 0.05 ） ; no significant difference was found in body weight, body mass index, waist hip ratio, liver function and levels of ferritin, glucose, lipid and uric acid between after treatment and 12 week after drug withdrawal （ P 〉 0.05 ）. After treatment, there were significant differences in body weight, body mass index, waist hip ratio, liver function, and levels of ferritin, glucose, lipid and uric acid between treatment group and ＂control group （P 〈 0.05 ） ; 12 week after drug withdrawal, there were significant differences in body weight, body mass index, waist hip ratio, liver function, levels of ferritin, glucose, lipid and blood uric acid between the two groups （ p 〈 0. 05 ）. ③ In each group, there was significant difference in fatty liver CT results between before and after treatment （ P 〈 0.05 ） ; after treatment significant difference was also found between the

关 键 词：非酒精性脂肪性肝病 通腑化瘀方 临床观察 

分 类 号：R575.5[医药卫生—消化系统]